These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 3684173)

  • 1. High-dose cytosine arabinoside, daunomycin and 6-thioguanine in relapsed or refractory acute nonlymphocytic leukemia.
    Garewal H; Durie BG; Greenberg B
    Oncology; 1987; 44(6):333-5. PubMed ID: 3684173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.
    Herzig RH; Lazarus HM; Wolff SN; Phillips GL; Herzig GP
    J Clin Oncol; 1985 Jul; 3(7):992-7. PubMed ID: 3894588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly.
    Kahn SB; Begg CB; Mazza JJ; Bennett JM; Bonner H; Glick JH
    J Clin Oncol; 1984 Aug; 2(8):865-70. PubMed ID: 6379120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
    Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
    J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: a Southwest Oncology Group study.
    Bigelow CL; Kopecky K; Files JC; Head D; Lipschitz DA; Grever M; Appelbaum FR
    Am J Hematol; 1995 Apr; 48(4):228-32. PubMed ID: 7717369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
    Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia.
    Lambertenghi-Deliliers G; Maiolo AT; Annaloro C; Cortelezzi A; Pogliani E; Ganzina F; Polli EE
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):1041-5. PubMed ID: 3478198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
    Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
    Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemia.
    Whitlock JA; Wells RJ; Hord JD; Janco RL; Greer JP; Gay JC; Edwards JR; McCurley TL; Lukens JN
    Leukemia; 1997 Feb; 11(2):185-9. PubMed ID: 9009078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update.
    Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
    Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
    Blood; 1987 Mar; 69(3):744-9. PubMed ID: 3469002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of childhood acute nonlymphocytic leukemia with high-dose cytosine arabinoside, 6-thioguanine, and doxorubicin without maintenance therapy: pilot study ANLL-80 of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A; Hhlen K; Colly LP; Vossen JM
    Pediatr Hematol Oncol; 1988; 5(2):93-102. PubMed ID: 3152962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reinduction chemotherapy for acute nonlymphocytic leukemia.
    Letendre L; Kiely JM; Hoagland HC
    Mayo Clin Proc; 1984 Sep; 59(9):618-21. PubMed ID: 6381915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daunomycin, cytosine arabinoside and 6-thioguanine (DAT) vs vincristine, cytosine arabinoside and 6-thioguanine (VAT) in the induction treatment of acute nonlymphocyte leukemia: a randomized collaborative study.
    Mandelli F; De Lipsis E; Grignani F; Martelli M; Liso V; Amadori S
    Med Pediatr Oncol; 1978; 4(3):231-40. PubMed ID: 277749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
    Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
    Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission.
    Stein AS; O'Donnell MR; Slovak ML; Nademanee A; Dagis A; Schmidt GM; Parker PM; Snyder DS; Smith EP; Somlo G; Margolin KA; Arber D; Niland J; Forman SJ
    Leukemia; 2000 Jul; 14(7):1191-6. PubMed ID: 10914541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission maintenance for acute nonlymphocytic leukemia: cytosine arabinoside plus 6-thioguanine versus a sequence of drug regimens.
    Presant CA; Berger NA; Klahr C; Phillips GL
    Cancer; 1980 Jul; 46(1):22-8. PubMed ID: 6930320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vincristine (NSC-67574), cytosine arabinoside (NSC-63878), 6 thioguanine (NSC-752) and daunorubicin (NSC-82151) (VAT-D): a pilot study of combination chemotherapy for remission induction in acute myeloid leukemia in adults.
    Sartiano GP; Pfrimmer WJ; Turner AR
    Med Pediatr Oncol; 1978; 4(3):205-12. PubMed ID: 277748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mitoxantrone and conventional-dose cytosine arabinoside for relapsed and refractory acute leukemia].
    Wakita A; Murase T; Uchida T; Fujiwara Y; Tanaka M; Ohkita T
    Gan To Kagaku Ryoho; 1992 May; 19(5):653-7. PubMed ID: 1580638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group.
    Lazarus HM; Vogler WR; Burns CP; Winton EF
    Cancer; 1989 Mar; 63(6):1055-9. PubMed ID: 2917307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.